Tokunbo Akande

Tokunbo Akande

Auto-generated profile, based on publicly available information

Tokunbo Akande

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
SISarah J Iribarren
Sarah J Iribarren
TATokunbo O Akande
Tokunbo O Akande
KKKendra Kamp
Kendra Kamp
DBDwight Barry
Dwight Barry
YKYazan G Kader
Yazan G Kader
ESElizabeth Suelzer
Elizabeth Suelzer
Background: Interventions aimed at modifying behavior for promoting health and disease management are traditionally resource intensive and difficult to scale. Mobile health apps are being used for these purposes; however, their effects on health outcomes have been mixed. Objective: This study aims to summarize the evidence of rigorously evaluated health-related apps on health outcomes and explore the effects of features present in studies that reported a statistically significant difference in health outcomes. Methods: A literature search was conducted in 7 databases (MEDLINE, Scopus, PsycINFO, CINAHL, Global Index Medicus, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews). A total of 5 reviewers independently screened and extracted the study characteristics. We used a random-effects model to calculate the pooled effect size estimates for meta-analysis. Sensitivity analysis was conducted based on follow-up time, stand-alone app interventions, level of personalization, and pilot studies. Logistic regression was used to examine the structure of app features. Results: From the database searches, 8230 records were initially identified. Of these, 172 met the inclusion criteria. Studies were predominantly conducted in high-income countries (164/172, 94.3%). The majority had follow-up periods of 6 months or less (143/172, 83.1%). Over half of the interventions were delivered by a stand-alone app (106/172, 61.6%). Static/one-size-fits-all (97/172, 56.4%) was the most common level of personalization. Intervention frequency was daily or more frequent for the majority of the studies (123/172, 71.5%). A total of 156 studies involving 21,422 participants reported continuous health outcome data. The use of an app to modify behavior (either as a stand-alone or as part of a larger intervention) confers a slight/weak advantage over standard care in health interventions (standardized mean difference=0.38 [95% CI 0.31-0.45]; I2=80%), although heterogeneity was high. Conclusions: The evidence in the literature demonstrates a steady increase in the rigorous evaluation of apps aimed at modifying behavior to promote health and manage disease. Although the literature is growing, the evidence that apps can improve health outcomes is weak. This finding may reflect the need for improved methodological and evaluative approaches to the development and assessment of health care improvement apps. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42018106868; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=106868

1 February 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
EHElliott R. Haut
Elliott R. Haut
LGLuis J. Garcia
Luis J. Garcia
HSHasan M. Shihab
Hasan M. Shihab
DBDaniel J. Brotman
Daniel J. Brotman
KSKent A. Stevens
Kent A. Stevens
SSSonal Singh
Sonal Singh
Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), affects as many as 600 000 Americans, killing more than 100 000 people each year and resulting in significant morbidity and mortality.1 Trauma is known to be one of the strongest risk factors for VTE. A prospective study2 reported rates of DVT as high as 58% among those who experience severe trauma without thromboprophylaxis, although other registry-based studies3,4 have reported lower rates. Guidelines recommend VTE prophylaxis with low-molecular-weight heparin in trauma.5,6

11 May 2014 in Tuberculosis Research and Treatment
Verified
Journal Article
Open access
PDF file
LKLakshmi Krishnan
Lakshmi Krishnan
TATokunbo Akande
Tokunbo Akande
ASAnita V. Shankar
Anita V. Shankar
KMKatherine N. McIntire
Katherine N. McIntire
CGCeline R. Gounder
Celine R. Gounder
WYWei-Teng Yang
Wei-Teng Yang
Background. Tuberculosis (TB) remains a significant global public health problem with known gender-related (male versus female) disparities. We reviewed the qualitative evidence (written/spoken narrative) for gender-related differences limiting TB service access from symptom onset to treatment initiation.Methods. Following a systematic process, we searched 12 electronic databases, included qualitative studies that assessed gender differences in accessing TB diagnostic and treatment services, abstracted data, and assessed study validity. Using a modified “inductive coding” system, we synthesized emergent themes within defined barriers and delays limiting access at the individual and provider/system levels and examined gender-related differences.Results. Among 13,448 studies, 28 studies were included. All were conducted in developing countries and assessed individual-level barriers; 11 (39%) assessed provider/system-level barriers, 18 (64%) surveyed persons with suspected or diagnosed TB, and 7 (25%) exclusively surveyed randomly sampled community members or health care workers. Each barrier affected both genders but had gender-variable nature and impact reflecting sociodemographic themes. Women experienced financial and physical dependence, lower general literacy, and household stigma, whereas men faced work-related financial and physical barriers and community-based stigma.Conclusions. In developing countries, barriers limiting access to TB care have context-specific gender-related differences that can inform integrated interventions to optimize TB services.

1 January 2014 in Tuberculosis Research and Treatment
Verified
Journal Article
Open access
PDF file
WYWei-Teng Yang
Wei-Teng Yang
CGCeline R. Gounder
Celine R. Gounder
TATokunbo Akande
Tokunbo Akande
JNJan-Walter De Neve
Jan-Walter De Neve
KMKatherine N. McIntire
Katherine N. McIntire
AGAmita Gupta
Amita Gupta
Background. Tuberculosis (TB) remains a global public health problem with known gender-related disparities. We reviewed the quantitative evidence for gender-related differences in accessing TB services from symptom onset to treatment initiation.Methods. Following a systematic review process, we: searched 12 electronic databases; included quantitative studies assessing gender differences in accessing TB diagnostic and treatment services; abstracted data; and assessed study validity. We defined barriers and delays at the individual and provider/system levels using a conceptual framework of the TB care continuum and examined gender-related differences.Results. Among 13,448 articles, 137 were included: many assessed individual-level barriers (52%) and delays (42%), 76% surveyed persons presenting for care with diagnosed or suspected TB, 24% surveyed community members, and two-thirds were from African and Asian regions. Many studies reported no gender differences. Among studies reporting disparities, women faced greater barriers (financial: 64% versus 36%; physical: 100% versus 0%; stigma: 85% versus 15%; health literacy: 67% versus 33%; and provider-/system-level: 100% versus 0%) and longer delays (presentation to diagnosis: 45% versus 0%) than men.Conclusions. Many studies found no quantitative gender-related differences in barriers and delays limiting access to TB services. When differences were identified, women experienced greater barriers and longer delays than men.

1 March 2016 in The Journal of Pediatrics
Verified
Journal Article
Closed access
PHPooja Hebbal
Pooja Hebbal
BRBarbara K. Russell
Barbara K. Russell
TATokunbo Akande
Tokunbo Akande
MNMasooma Niazi
Masooma Niazi
SHStefan F.H. Hagmann
Stefan F.H. Hagmann
MPMurli U. Purswani
Murli U. Purswani

18 June 2020 in JMIR Preprints
Verified
Preprint
Open access
SISarah J Iribarren
Sarah J Iribarren
TATokunbo O Akande
Tokunbo O Akande
KKKendra Kamp
Kendra Kamp
DBDwight Barry
Dwight Barry
YKYazan G Kader
Yazan G Kader
ESElizabeth Suelzer
Elizabeth Suelzer
BACKGROUND Interventions aimed at modifying behavior for promoting health and disease management are traditionally resource intensive and difficult to scale. Mobile health apps are being used for these purposes; however, their effects on health outcomes have been mixed. OBJECTIVE This study aims to summarize the evidence of rigorously evaluated health-related apps on health outcomes and explore the effects of features present in studies that reported a statistically significant difference in health outcomes. METHODS A literature search was conducted in 7 databases (MEDLINE, Scopus, PsycINFO, CINAHL, Global Index Medicus, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews). A total of 5 reviewers independently screened and extracted the study characteristics. We used a random-effects model to calculate the pooled effect size estimates for meta-analysis. Sensitivity analysis was conducted based on follow-up time, stand-alone app interventions, level of personalization, and pilot studies. Logistic regression was used to examine the structure of app features. RESULTS From the database searches, 8230 records were initially identified. Of these, 172 met the inclusion criteria. Studies were predominantly conducted in high-income countries (164/172, 94.3%). The majority had follow-up periods of 6 months or less (143/172, 83.1%). Over half of the interventions were delivered by a stand-alone app (106/172, 61.6%). Static/one-size-fits-all (97/172, 56.4%) was the most common level of personalization. Intervention frequency was daily or more frequent for the majority of the studies (123/172, 71.5%). A total of 156 studies involving 21,422 participants reported continuous health outcome data. The use of an app to modify behavior (either as a stand-alone or as part of a larger intervention) confers a slight/weak advantage over standard care in health interventions (standardized mean difference=0.38 [95% CI 0.31-0.45]; I2=80%), although heterogeneity was high. CONCLUSIONS The evidence in the literature demonstrates a steady increase in the rigorous evaluation of apps aimed at modifying behavior to promote health and manage disease. Although the literature is growing, the evidence that apps can improve health outcomes is weak. This finding may reflect the need for improved methodological and evaluative approaches to the development and assessment of health care improvement apps. CLINICALTRIAL PROSPERO International Prospective Register of Systematic Reviews CRD42018106868; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=106868